View Future GrowthPharmanutra 過去の業績過去 基準チェック /66Pharmanutraは、平均年間7.1%の収益成長を遂げていますが、 Personal Products業界の収益は、年間 成長しています。収益は、平均年間10.3% 16.6%収益成長率で 成長しています。 Pharmanutraの自己資本利益率は28.1%であり、純利益率は15.2%です。主要情報7.14%収益成長率7.37%EPS成長率Personal Products 業界の成長13.59%収益成長率16.55%株主資本利益率28.12%ネット・マージン15.15%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 13First quarter 2026 earnings released: EPS: €0.36 (vs €0.25 in 1Q 2025)First quarter 2026 results: EPS: €0.36 (up from €0.25 in 1Q 2025). Revenue: €33.4m (up 25% from 1Q 2025). Net income: €3.46m (up 42% from 1Q 2025). Profit margin: 10% (up from 9.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.Reported Earnings • Mar 19Full year 2025 earnings: Revenues exceed analyst expectationsFull year 2025 results: Revenue: €134.0m (up 15% from FY 2024). Net income: €20.0m (up 20% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue exceeded analyst estimates by 1.1%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe.Reported Earnings • Sep 11Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €36.3m (up 11% from 2Q 2024). Net income: €6.75m (up 7.7% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe.Reported Earnings • Mar 30Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: €1.73 (up from €1.33 in FY 2023). Revenue: €116.1m (up 15% from FY 2023). Net income: €16.6m (up 29% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025Reported Earnings • Nov 15Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €28.0m (up 28% from 3Q 2023). Net income: €4.27m (up 71% from 3Q 2023). Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • May 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €89.90, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €61.16 per share.Reported Earnings • May 13First quarter 2026 earnings released: EPS: €0.36 (vs €0.25 in 1Q 2025)First quarter 2026 results: EPS: €0.36 (up from €0.25 in 1Q 2025). Revenue: €33.4m (up 25% from 1Q 2025). Net income: €3.46m (up 42% from 1Q 2025). Profit margin: 10% (up from 9.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.Price Target Changed • May 12Price target increased by 11% to €91.33Up from €82.33, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of €88.00. Stock is up 68% over the past year. The company is forecast to post earnings per share of €2.58 for next year compared to €2.09 last year.Declared Dividend • May 02Dividend increased to €1.20Dividend of €1.20 is 20% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 1.5%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (70% cash payout ratio). The dividend has increased by an average of 18% per year over the past 8 years and payments have been stable during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.お知らせ • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.Reported Earnings • Mar 19Full year 2025 earnings: Revenues exceed analyst expectationsFull year 2025 results: Revenue: €134.0m (up 15% from FY 2024). Net income: €20.0m (up 20% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue exceeded analyst estimates by 1.1%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe.Buy Or Sell Opportunity • Mar 18Now 30% overvalued after recent price riseOver the last 90 days, the stock has risen 40% to €74.80. The fair value is estimated to be €57.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.Buy Or Sell Opportunity • Mar 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to €66.90. The fair value is estimated to be €55.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.Buy Or Sell Opportunity • Feb 16Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to €64.70. The fair value is estimated to be €52.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.分析記事 • Nov 29Why Investors Shouldn't Be Surprised By Pharmanutra S.p.A.'s (BIT:PHN) 26% Share Price SurgePharmanutra S.p.A. ( BIT:PHN ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €58.00, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Personal Products industry in Europe. Total loss to shareholders of 1.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.72 per share.分析記事 • Nov 27Here's Why Pharmanutra (BIT:PHN) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Nov 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €51.60, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Personal Products industry in Europe. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.66 per share.Buy Or Sell Opportunity • Nov 11Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 8.1% to €51.00. The fair value is estimated to be €41.95, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 3.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 2.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (122% cash payout ratio). Share price has been volatile over the past 3 months (2.9% average weekly change).Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €46.85, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 17x in the Personal Products industry in Europe. Total loss to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.74 per share.Buy Or Sell Opportunity • Oct 02Now 24% overvaluedThe stock has been flat over the last 90 days, currently trading at €46.85. The fair value is estimated to be €37.74, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 3.4%. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 49% in the next 2 years.Reported Earnings • Sep 11Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €36.3m (up 11% from 2Q 2024). Net income: €6.75m (up 7.7% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe.Buy Or Sell Opportunity • Jun 02Now 21% overvaluedOver the last 90 days, the stock has fallen 8.5% to €50.80. The fair value is estimated to be €42.00, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.Buy Or Sell Opportunity • May 16Now 22% overvaluedThe stock has been flat over the last 90 days, currently trading at €51.90. The fair value is estimated to be €42.44, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.Upcoming Dividend • Apr 28Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Italian dividend payers (5.7%). Lower than average of industry peers (2.3%).Recent Insider Transactions • Apr 17Delegate Advisor recently bought €132k worth of stockOn the 11th of April, Carlo Volpi bought around 3k shares on-market at roughly €47.75 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Carlo has been a buyer over the last 12 months, purchasing a net total of €225k worth in shares.Reported Earnings • Mar 30Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: €1.73 (up from €1.33 in FY 2023). Revenue: €116.1m (up 15% from FY 2023). Net income: €16.6m (up 29% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.分析記事 • Mar 20Pharmanutra's (BIT:PHN) Dividend Will Be Increased To €1.00Pharmanutra S.p.A.'s ( BIT:PHN ) dividend will be increasing from last year's payment of the same period to €1.00 on...Declared Dividend • Mar 19Dividend increased to €1.00Dividend of €1.00 is 18% higher than last year. Ex-date: 5th May 2025 Payment date: 7th May 2025 Dividend yield will be 2.0%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 17% per year over the past 7 years and payments have been stable during that time. EPS is expected to grow by 49% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.お知らせ • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.New Risk • Jan 13New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.お知らせ • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025Reported Earnings • Nov 15Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €28.0m (up 28% from 3Q 2023). Net income: €4.27m (up 71% from 3Q 2023). Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.Reported Earnings • Sep 11Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)Second quarter 2024 results: EPS: €0.67 (up from €0.19 in 2Q 2023). Revenue: €33.2m (up 27% from 2Q 2023). Net income: €6.27m (up 248% from 2Q 2023). Profit margin: 19% (up from 6.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.分析記事 • Sep 11Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) EarningsPharmanutra S.p.A.'s ( BIT:PHN ) price-to-earnings (or "P/E") ratio of 52.9x might make it look like a strong sell...Reported Earnings • May 17First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)First quarter 2024 results: EPS: €0.27 (down from €0.56 in 1Q 2023). Revenue: €24.0m (up 1.3% from 1Q 2023). Net income: €2.63m (down 52% from 1Q 2023). Profit margin: 11% (down from 23% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Upcoming Dividend • Apr 29Upcoming dividend of €0.85 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Italian dividend payers (5.7%). Lower than average of industry peers (2.1%).分析記事 • Mar 23Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft EarningsPharmanutra S.p.A.'s ( BIT:PHN ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...Reported Earnings • Mar 18Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: €1.33 (down from €1.56 in FY 2022). Revenue: €102.0m (up 23% from FY 2022). Net income: €12.8m (down 15% from FY 2022). Profit margin: 13% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 14Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023.お知らせ • Jan 13Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)Third quarter 2023 results: EPS: €0.26 (down from €0.48 in 3Q 2022). Revenue: €22.3m (up 8.2% from 3Q 2022). Net income: €2.50m (down 46% from 3Q 2022). Profit margin: 11% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Sep 13Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)Second quarter 2023 results: EPS: €0.19 (down from €0.49 in 2Q 2022). Revenue: €25.9m (up 24% from 2Q 2022). Net income: €1.80m (down 62% from 2Q 2022). Profit margin: 7.0% (down from 23% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 18First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €24.6m (up 30% from 1Q 2022). Net income: €5.43m (up 56% from 1Q 2022). Profit margin: 22% (up from 19% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Personal Products industry in Italy.Upcoming Dividend • May 01Upcoming dividend of €0.80 per share at 1.6% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Italian dividend payers (5.1%). Lower than average of industry peers (1.8%).Reported Earnings • Mar 18Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: €1.56 (up from €1.42 in FY 2021). Revenue: €83.4m (up 22% from FY 2021). Net income: €15.0m (up 9.3% from FY 2021). Profit margin: 18% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 13+ 2 more updatesPharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023Pharmanutra S.p.A. announced that they will report fiscal year 2022 results on Mar 16, 2023Reported Earnings • Nov 20Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: €0.48 (up from €0.39 in 3Q 2021). Revenue: €20.5m (up 20% from 3Q 2021). Net income: €4.61m (up 20% from 3Q 2021). Profit margin: 23% (in line with 3Q 2021). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 12Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: €0.48 (up from €0.39 in 3Q 2021). Revenue: €20.8m (up 22% from 3Q 2021). Net income: €4.61m (up 20% from 3Q 2021). Profit margin: 22% (in line with 3Q 2021). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 26Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Reported Earnings • Sep 16Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: €0.49 (up from €0.47 in 2Q 2021). Revenue: €21.1m (up 17% from 2Q 2021). Net income: €4.75m (up 4.7% from 2Q 2021). Profit margin: 23% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 4.9%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 16These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt SafelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: €0.36 (up from €0.26 in 1Q 2021). Revenue: €19.0m (up 33% from 1Q 2021). Net income: €3.49m (up 39% from 1Q 2021). Profit margin: 18% (in line with 1Q 2021). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Over the next year, revenue is forecast to grow 15%, compared to a 17% growth forecast for the industry in Italy. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Jan 11Pharmanutra (BIT:PHN) Could Easily Take On More DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Nov 10Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €17.0m (up 46% from 3Q 2020). Net income: €3.85m (up 122% from 3Q 2020). Profit margin: 23% (up from 15% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Nov 02Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't IdealWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 18% share price gain to €62.40, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 32x in the Personal Products industry in Europe. Total returns to shareholders of 339% over the past three years.Price Target Changed • Aug 05Price target increased to €59.33Up from €53.67, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of €60.00. Stock is up 159% over the past year.分析記事 • Aug 03Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital AroundWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...Price Target Changed • Jun 16Price target increased to €50.67Up from €45.33, the current price target is an average from 3 analysts. New target price is 11% above last closing price of €45.60. Stock is up 93% over the past year.Valuation Update With 7 Day Price Move • Jun 10Investor sentiment improved over the past weekAfter last week's 16% share price gain to €42.30, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 29x in the Personal Products industry in Europe. Total returns to shareholders of 225% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.58 per share.Price Target Changed • Jun 03Price target increased to €45.00Up from €42.00, the current price target is an average from 2 analysts. New target price is 25% above last closing price of €36.10. Stock is up 49% over the past year.分析記事 • May 20Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Upcoming Dividend • Apr 26Upcoming dividend of €0.67 per shareEligible shareholders must have bought the stock before 03 May 2021. Payment date: 05 May 2021. Trailing yield: 1.8%. Lower than top quartile of Italian dividend payers (4.0%). Lower than average of industry peers (2.1%).分析記事 • Apr 19Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...Reported Earnings • Mar 24Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.7m (up 9.0% from FY 2019). Net income: €14.1m (up 67% from FY 2019). Profit margin: 24% (up from 16% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Mar 10Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?Pharmanutra (BIT:PHN) has had a great run on the share market with its stock up by a significant 12% over the last...分析記事 • Feb 17Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...分析記事 • Feb 01Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Jan 18Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?Could Pharmanutra S.p.A. ( BIT:PHN ) be an attractive dividend share to own for the long haul? Investors are often...分析記事 • Jan 04Is Pharmanutra (BIT:PHN) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Dec 22Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total ReturnThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...Is New 90 Day High Low • Dec 12New 90-day high: €33.70The company is up 49% from its price of €22.60 on 11 September 2020. The Italian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 1.0% over the same period.分析記事 • Dec 08Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?Every investor in Pharmanutra S.p.A. ( BIT:PHN ) should be aware of the most powerful shareholder groups. Institutions...Valuation Update With 7 Day Price Move • Dec 07Market bids up stock over the past weekAfter last week's 17% share price gain to €33.30, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 19.7x. This compares to an average P/E of 21x in the Personal Products industry in Europe. Total returns to shareholders over the past three years are 183%.分析記事 • Nov 23Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?Pharmanutra's (BIT:PHN) stock is up by a considerable 20% over the past three months. Given that the market rewards...Is New 90 Day High Low • Nov 12New 90-day high: €28.80The company is up 24% from its price of €23.30 on 14 August 2020. The Italian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 10.0% over the same period.Reported Earnings • Nov 11Third quarter 2020 earnings released: EPS €0.18The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €13.0m (down 9.4% from 3Q 2019). Net income: €1.74m (down 22% from 3Q 2019). Profit margin: 13% (down from 16% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 30% per year and the company’s share price has also increased by 30% per year.Is New 90 Day High Low • Oct 05New 90-day high: €27.20The company is up 13% from its price of €24.00 on 07 July 2020. The Italian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 2.0% over the same period.Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total profits of €14.2m, up 58% from the prior year. Total revenue was €57.9m over the last 12 months, up 16% from the prior year.収支内訳Pharmanutra の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BIT:PHN 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Mar 261392135031 Dec 251322033030 Sep 251271732030 Jun 251221731031 Mar 251191629031 Dec 241161727030 Sep 241131626030 Jun 241081424031 Mar 241011123031 Dec 231011323030 Sep 23951221030 Jun 23931420031 Mar 23881618031 Dec 22831517030 Sep 22791615030 Jun 22761514031 Mar 22731513031 Dec 21681412030 Sep 21651412030 Jun 21601111031 Mar 21571410031 Dec 20571410030 Sep 20581410030 Jun 20581410031 Mar 2055910031 Dec 195489030 Sep 194988030 Jun 195097031 Mar 194898031 Dec 184798030 Sep 184488030 Jun 184177031 Mar 184067031 Dec 173866030 Sep 173756030 Jun 173555031 Mar 173445031 Dec 163345031 Dec 1526350質の高い収益: PHNは 高品質の収益 を持っています。利益率の向上: PHNの現在の純利益率 (15.2%)は、昨年(13.8%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PHNの収益は過去 5 年間で年間7.1%増加しました。成長の加速: PHNの過去 1 年間の収益成長率 ( 28.1% ) は、5 年間の平均 ( 年間7.1%を上回っています。収益対業界: PHNの過去 1 年間の収益成長率 ( 28.1% ) はPersonal Products業界2.8%を上回りました。株主資本利益率高いROE: PHNの 自己資本利益率 ( 28.1% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHousehold 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 04:29終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmanutra S.p.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Anna FrontaniBerenbergAndrea RandoneIntermonte SIM S.p.A.Giorgio TavoliniIntermonte SIM S.p.A.3 その他のアナリストを表示
Reported Earnings • May 13First quarter 2026 earnings released: EPS: €0.36 (vs €0.25 in 1Q 2025)First quarter 2026 results: EPS: €0.36 (up from €0.25 in 1Q 2025). Revenue: €33.4m (up 25% from 1Q 2025). Net income: €3.46m (up 42% from 1Q 2025). Profit margin: 10% (up from 9.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.
Reported Earnings • Mar 19Full year 2025 earnings: Revenues exceed analyst expectationsFull year 2025 results: Revenue: €134.0m (up 15% from FY 2024). Net income: €20.0m (up 20% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue exceeded analyst estimates by 1.1%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe.
Reported Earnings • Sep 11Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €36.3m (up 11% from 2Q 2024). Net income: €6.75m (up 7.7% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe.
Reported Earnings • Mar 30Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: €1.73 (up from €1.33 in FY 2023). Revenue: €116.1m (up 15% from FY 2023). Net income: €16.6m (up 29% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025
Reported Earnings • Nov 15Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €28.0m (up 28% from 3Q 2023). Net income: €4.27m (up 71% from 3Q 2023). Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.
Valuation Update With 7 Day Price Move • May 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €89.90, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €61.16 per share.
Reported Earnings • May 13First quarter 2026 earnings released: EPS: €0.36 (vs €0.25 in 1Q 2025)First quarter 2026 results: EPS: €0.36 (up from €0.25 in 1Q 2025). Revenue: €33.4m (up 25% from 1Q 2025). Net income: €3.46m (up 42% from 1Q 2025). Profit margin: 10% (up from 9.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year.
Price Target Changed • May 12Price target increased by 11% to €91.33Up from €82.33, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of €88.00. Stock is up 68% over the past year. The company is forecast to post earnings per share of €2.58 for next year compared to €2.09 last year.
Declared Dividend • May 02Dividend increased to €1.20Dividend of €1.20 is 20% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 1.5%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (70% cash payout ratio). The dividend has increased by an average of 18% per year over the past 8 years and payments have been stable during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
お知らせ • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.
Reported Earnings • Mar 19Full year 2025 earnings: Revenues exceed analyst expectationsFull year 2025 results: Revenue: €134.0m (up 15% from FY 2024). Net income: €20.0m (up 20% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue exceeded analyst estimates by 1.1%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe.
Buy Or Sell Opportunity • Mar 18Now 30% overvalued after recent price riseOver the last 90 days, the stock has risen 40% to €74.80. The fair value is estimated to be €57.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
Buy Or Sell Opportunity • Mar 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to €66.90. The fair value is estimated to be €55.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
Buy Or Sell Opportunity • Feb 16Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to €64.70. The fair value is estimated to be €52.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
分析記事 • Nov 29Why Investors Shouldn't Be Surprised By Pharmanutra S.p.A.'s (BIT:PHN) 26% Share Price SurgePharmanutra S.p.A. ( BIT:PHN ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €58.00, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Personal Products industry in Europe. Total loss to shareholders of 1.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.72 per share.
分析記事 • Nov 27Here's Why Pharmanutra (BIT:PHN) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €51.60, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Personal Products industry in Europe. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.66 per share.
Buy Or Sell Opportunity • Nov 11Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 8.1% to €51.00. The fair value is estimated to be €41.95, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 3.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.
New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 2.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (122% cash payout ratio). Share price has been volatile over the past 3 months (2.9% average weekly change).
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €46.85, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 17x in the Personal Products industry in Europe. Total loss to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.74 per share.
Buy Or Sell Opportunity • Oct 02Now 24% overvaluedThe stock has been flat over the last 90 days, currently trading at €46.85. The fair value is estimated to be €37.74, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 3.4%. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 49% in the next 2 years.
Reported Earnings • Sep 11Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €36.3m (up 11% from 2Q 2024). Net income: €6.75m (up 7.7% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe.
Buy Or Sell Opportunity • Jun 02Now 21% overvaluedOver the last 90 days, the stock has fallen 8.5% to €50.80. The fair value is estimated to be €42.00, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
Buy Or Sell Opportunity • May 16Now 22% overvaluedThe stock has been flat over the last 90 days, currently trading at €51.90. The fair value is estimated to be €42.44, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
Upcoming Dividend • Apr 28Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Italian dividend payers (5.7%). Lower than average of industry peers (2.3%).
Recent Insider Transactions • Apr 17Delegate Advisor recently bought €132k worth of stockOn the 11th of April, Carlo Volpi bought around 3k shares on-market at roughly €47.75 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Carlo has been a buyer over the last 12 months, purchasing a net total of €225k worth in shares.
Reported Earnings • Mar 30Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: €1.73 (up from €1.33 in FY 2023). Revenue: €116.1m (up 15% from FY 2023). Net income: €16.6m (up 29% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
分析記事 • Mar 20Pharmanutra's (BIT:PHN) Dividend Will Be Increased To €1.00Pharmanutra S.p.A.'s ( BIT:PHN ) dividend will be increasing from last year's payment of the same period to €1.00 on...
Declared Dividend • Mar 19Dividend increased to €1.00Dividend of €1.00 is 18% higher than last year. Ex-date: 5th May 2025 Payment date: 7th May 2025 Dividend yield will be 2.0%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 17% per year over the past 7 years and payments have been stable during that time. EPS is expected to grow by 49% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
お知らせ • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.
New Risk • Jan 13New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.
お知らせ • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025
Reported Earnings • Nov 15Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €28.0m (up 28% from 3Q 2023). Net income: €4.27m (up 71% from 3Q 2023). Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.
Reported Earnings • Sep 11Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)Second quarter 2024 results: EPS: €0.67 (up from €0.19 in 2Q 2023). Revenue: €33.2m (up 27% from 2Q 2023). Net income: €6.27m (up 248% from 2Q 2023). Profit margin: 19% (up from 6.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.
分析記事 • Sep 11Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) EarningsPharmanutra S.p.A.'s ( BIT:PHN ) price-to-earnings (or "P/E") ratio of 52.9x might make it look like a strong sell...
Reported Earnings • May 17First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)First quarter 2024 results: EPS: €0.27 (down from €0.56 in 1Q 2023). Revenue: €24.0m (up 1.3% from 1Q 2023). Net income: €2.63m (down 52% from 1Q 2023). Profit margin: 11% (down from 23% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Upcoming Dividend • Apr 29Upcoming dividend of €0.85 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Italian dividend payers (5.7%). Lower than average of industry peers (2.1%).
分析記事 • Mar 23Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft EarningsPharmanutra S.p.A.'s ( BIT:PHN ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...
Reported Earnings • Mar 18Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: €1.33 (down from €1.56 in FY 2022). Revenue: €102.0m (up 23% from FY 2022). Net income: €12.8m (down 15% from FY 2022). Profit margin: 13% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 14Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023.
お知らせ • Jan 13Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024
Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)Third quarter 2023 results: EPS: €0.26 (down from €0.48 in 3Q 2022). Revenue: €22.3m (up 8.2% from 3Q 2022). Net income: €2.50m (down 46% from 3Q 2022). Profit margin: 11% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Sep 13Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)Second quarter 2023 results: EPS: €0.19 (down from €0.49 in 2Q 2022). Revenue: €25.9m (up 24% from 2Q 2022). Net income: €1.80m (down 62% from 2Q 2022). Profit margin: 7.0% (down from 23% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 18First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €24.6m (up 30% from 1Q 2022). Net income: €5.43m (up 56% from 1Q 2022). Profit margin: 22% (up from 19% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Personal Products industry in Italy.
Upcoming Dividend • May 01Upcoming dividend of €0.80 per share at 1.6% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Italian dividend payers (5.1%). Lower than average of industry peers (1.8%).
Reported Earnings • Mar 18Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: €1.56 (up from €1.42 in FY 2021). Revenue: €83.4m (up 22% from FY 2021). Net income: €15.0m (up 9.3% from FY 2021). Profit margin: 18% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 13+ 2 more updatesPharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023Pharmanutra S.p.A. announced that they will report fiscal year 2022 results on Mar 16, 2023
Reported Earnings • Nov 20Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: €0.48 (up from €0.39 in 3Q 2021). Revenue: €20.5m (up 20% from 3Q 2021). Net income: €4.61m (up 20% from 3Q 2021). Profit margin: 23% (in line with 3Q 2021). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 12Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: €0.48 (up from €0.39 in 3Q 2021). Revenue: €20.8m (up 22% from 3Q 2021). Net income: €4.61m (up 20% from 3Q 2021). Profit margin: 22% (in line with 3Q 2021). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 26Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Reported Earnings • Sep 16Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: €0.49 (up from €0.47 in 2Q 2021). Revenue: €21.1m (up 17% from 2Q 2021). Net income: €4.75m (up 4.7% from 2Q 2021). Profit margin: 23% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 4.9%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 16These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt SafelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: €0.36 (up from €0.26 in 1Q 2021). Revenue: €19.0m (up 33% from 1Q 2021). Net income: €3.49m (up 39% from 1Q 2021). Profit margin: 18% (in line with 1Q 2021). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Over the next year, revenue is forecast to grow 15%, compared to a 17% growth forecast for the industry in Italy. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Jan 11Pharmanutra (BIT:PHN) Could Easily Take On More DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Nov 10Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €17.0m (up 46% from 3Q 2020). Net income: €3.85m (up 122% from 3Q 2020). Profit margin: 23% (up from 15% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Nov 02Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't IdealWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 18% share price gain to €62.40, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 32x in the Personal Products industry in Europe. Total returns to shareholders of 339% over the past three years.
Price Target Changed • Aug 05Price target increased to €59.33Up from €53.67, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of €60.00. Stock is up 159% over the past year.
分析記事 • Aug 03Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital AroundWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
Price Target Changed • Jun 16Price target increased to €50.67Up from €45.33, the current price target is an average from 3 analysts. New target price is 11% above last closing price of €45.60. Stock is up 93% over the past year.
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment improved over the past weekAfter last week's 16% share price gain to €42.30, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 29x in the Personal Products industry in Europe. Total returns to shareholders of 225% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.58 per share.
Price Target Changed • Jun 03Price target increased to €45.00Up from €42.00, the current price target is an average from 2 analysts. New target price is 25% above last closing price of €36.10. Stock is up 49% over the past year.
分析記事 • May 20Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Upcoming Dividend • Apr 26Upcoming dividend of €0.67 per shareEligible shareholders must have bought the stock before 03 May 2021. Payment date: 05 May 2021. Trailing yield: 1.8%. Lower than top quartile of Italian dividend payers (4.0%). Lower than average of industry peers (2.1%).
分析記事 • Apr 19Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...
Reported Earnings • Mar 24Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.7m (up 9.0% from FY 2019). Net income: €14.1m (up 67% from FY 2019). Profit margin: 24% (up from 16% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Mar 10Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?Pharmanutra (BIT:PHN) has had a great run on the share market with its stock up by a significant 12% over the last...
分析記事 • Feb 17Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...
分析記事 • Feb 01Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • Jan 18Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?Could Pharmanutra S.p.A. ( BIT:PHN ) be an attractive dividend share to own for the long haul? Investors are often...
分析記事 • Jan 04Is Pharmanutra (BIT:PHN) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Dec 22Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total ReturnThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Is New 90 Day High Low • Dec 12New 90-day high: €33.70The company is up 49% from its price of €22.60 on 11 September 2020. The Italian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 1.0% over the same period.
分析記事 • Dec 08Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?Every investor in Pharmanutra S.p.A. ( BIT:PHN ) should be aware of the most powerful shareholder groups. Institutions...
Valuation Update With 7 Day Price Move • Dec 07Market bids up stock over the past weekAfter last week's 17% share price gain to €33.30, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 19.7x. This compares to an average P/E of 21x in the Personal Products industry in Europe. Total returns to shareholders over the past three years are 183%.
分析記事 • Nov 23Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?Pharmanutra's (BIT:PHN) stock is up by a considerable 20% over the past three months. Given that the market rewards...
Is New 90 Day High Low • Nov 12New 90-day high: €28.80The company is up 24% from its price of €23.30 on 14 August 2020. The Italian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 10.0% over the same period.
Reported Earnings • Nov 11Third quarter 2020 earnings released: EPS €0.18The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €13.0m (down 9.4% from 3Q 2019). Net income: €1.74m (down 22% from 3Q 2019). Profit margin: 13% (down from 16% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 30% per year and the company’s share price has also increased by 30% per year.
Is New 90 Day High Low • Oct 05New 90-day high: €27.20The company is up 13% from its price of €24.00 on 07 July 2020. The Italian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 2.0% over the same period.
Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total profits of €14.2m, up 58% from the prior year. Total revenue was €57.9m over the last 12 months, up 16% from the prior year.